We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology ...
Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. Quest Flow ...
In patients with newly diagnosed multiple myeloma (MM) who are not eligible for stem cell transplant, the regimen of isatuximab plus lenalidomide, dexamethasone, and bortezomib (also known as Isa-VRd) ...
Dec 10 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up ...
Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...
Cook, R. D., & Weisberg, S. (1982). Residuals and Influence in Regression (1st ed.). Chapman & Hall.
ABSTRACT: This study investigates the impact of wage structure on employee satisfaction, motivation, and retention in Thailand’s textile manufacturing industry. Despite the recognized importance of ...
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an ...
Multiple sclerosis (MS) has long been regarded as a disease with different subtypes such as “relapsing” or “progressive.” An international study, published on August 20, 2025, in Nature Medicine under ...
Discover a smarter way to grow with Learn with Jay, your trusted source for mastering valuable skills and unlocking your full potential. Whether you're aiming to advance your career, build better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results